Your browser doesn't support javascript.
loading
Benzodiazepine administration patterns before escalation to second-line medications in pediatric refractory convulsive status epilepticus.
Sheehan, Theodore; Amengual-Gual, Marta; Vasquez, Alejandra; Abend, Nicholas S; Anderson, Anne; Appavu, Brian; Arya, Ravindra; Barcia Aguilar, Cristina; Brenton, J Nicholas; Carpenter, Jessica L; Chapman, Kevin E; Clark, Justice; Farias-Moeller, Raquel; Gaillard, William D; Gaínza-Lein, Marina; Glauser, Tracy A; Goldstein, Joshua L; Goodkin, Howard P; Guerriero, Réjean M; Huh, Linda; Jackson, Michele; Kapur, Kush; Kahoud, Robert; Lai, Yi-Chen; McDonough, Tiffani L; Mikati, Mohamad A; Morgan, Lindsey A; Novotny, Edward J; Ostendorf, Adam P; Payne, Eric T; Peariso, Katrina; Piantino, Juan; Reece, Latania; Riviello, James J; Sands, Tristan T; Sannagowdara, Kumar; Shellhaas, Renee; Smith, Garnett; Tasker, Robert C; Tchapyjnikov, Dmitry; Topjian, Alexis A; Wainwright, Mark S; Wilfong, Angus; Williams, Korwyn; Zhang, Bo; Loddenkemper, Tobias.
Afiliação
  • Sheehan T; Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Amengual-Gual M; Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Vasquez A; Pediatric Neurology Unit, Department of Pediatrics, Son Espases University Hospital, University of the Balearic Islands, Palma, Spain.
  • Abend NS; Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Anderson A; Division of Child and Adolescent Neurology, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Appavu B; Division of Neurology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Arya R; Section of Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
  • Barcia Aguilar C; Department of Pediatrics, University of Arizona College of Medicine and Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona, USA.
  • Brenton JN; Division of Neurology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
  • Carpenter JL; Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Chapman KE; Department of Child Neurology, La Paz University Hospital, Autonomous University of Madrid, Madrid, Spain.
  • Clark J; Department of Neurology and Pediatrics, University of Virginia Health System, Charlottesville, Virginia, USA.
  • Farias-Moeller R; Center for Neuroscience, Children's National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
  • Gaillard WD; Departments of Pediatrics and Neurology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Gaínza-Lein M; Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Glauser TA; Department of Neurology, Division of Pediatric Neurology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Goldstein JL; Center for Neuroscience, Children's National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
  • Goodkin HP; Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Guerriero RM; Faculty of Medicine, Austral University of Chile, Valdivia, Chile.
  • Huh L; Division of Neurology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
  • Jackson M; Ruth D. & Ken M. Davee Pediatric Neurocritical Care Program, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Kapur K; Department of Neurology and Pediatrics, University of Virginia Health System, Charlottesville, Virginia, USA.
  • Kahoud R; Division of Pediatric and Developmental Neurology, Departments of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Lai YC; Division of Neurology, Department of Paediatrics, BC Children's Hospital, University of British Columbia, Vancouver, Canada.
  • McDonough TL; Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Mikati MA; Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Morgan LA; Division of Pediatric Critical Care Medicine, Department of Pediatrics, Mayo Clinic, Rochester, Minnesota, USA.
  • Novotny EJ; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Ostendorf AP; Section of Pediatric Critical Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
  • Payne ET; Division of Child Neurology, Department of Neurology, Columbia University Medical Center, Columbia University, New York, New York, USA.
  • Peariso K; Division of Pediatric Neurology, Duke University Medical Center, Duke University, Durham, North Carolina, USA.
  • Piantino J; Departments of Neurology and Pediatrics, Division of Pediatric Neurology, University of Washington, Seattle Children's Hospital, Seattle, Washington, USA.
  • Reece L; Departments of Neurology and Pediatrics, Division of Pediatric Neurology, University of Washington, Seattle Children's Hospital, Seattle, Washington, USA.
  • Riviello JJ; Department of Pediatrics, Nationwide Children's Hospital, Ohio State University, Columbus, Ohio, USA.
  • Sands TT; Division of Neurology, Department of Pediatrics, Alberta Children's Hospital, Calgary, Alberta, Canada.
  • Sannagowdara K; Division of Neurology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
  • Shellhaas R; Division of Neurology, Doernbecher Children's Hospital, Oregon Health & Science University, Portland, Oregon, USA.
  • Smith G; Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Tasker RC; Section of Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
  • Tchapyjnikov D; Division of Child Neurology, Department of Neurology, Columbia University Medical Center, Columbia University, New York, New York, USA.
  • Topjian AA; Department of Neurology, Division of Pediatric Neurology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Wainwright MS; Department of Pediatrics, Division of Pediatric Neurology, University of Michigan, Ann Arbor, Michigan, USA.
  • Wilfong A; Department of Pediatrics, Division of Pediatric Neurology, University of Michigan, Ann Arbor, Michigan, USA.
  • Williams K; Division of Critical Care, Departments of Neurology, Anesthesiology, and Perioperative and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Zhang B; Division of Pediatric Neurology, Duke University Medical Center, Duke University, Durham, North Carolina, USA.
  • Loddenkemper T; Department of Pediatrics, Montana Children's Hospital, Kalispell Regional Medical Center, Kalispell, Montana, USA.
Epilepsia ; 62(11): 2766-2777, 2021 11.
Article em En | MEDLINE | ID: mdl-34418087
ABSTRACT

OBJECTIVE:

This study was undertaken to evaluate benzodiazepine (BZD) administration patterns before transitioning to non-BZD antiseizure medication (ASM) in pediatric patients with refractory convulsive status epilepticus (rSE).

METHODS:

This retrospective multicenter study in the United States and Canada used prospectively collected observational data from children admitted with rSE between 2011 and 2020. Outcome variables were the number of BZDs given before the first non-BZD ASM, and the number of BZDs administered after 30 and 45 min from seizure onset and before escalating to non-BZD ASM.

RESULTS:

We included 293 patients with a median (interquartile range) age of 3.8 (1.3-9.3) years. Thirty-six percent received more than two BZDs before escalating, and the later the treatment initiation was after seizure onset, the less likely patients were to receive multiple BZD doses before transitioning (incidence rate ratio [IRR] = .998, 95% confidence interval [CI] = .997-.999 per minute, p = .01). Patients received BZDs beyond 30 and 45 min in 57.3% and 44.0% of cases, respectively. Patients with out-of-hospital seizure onset were more likely to receive more doses of BZDs beyond 30 min (IRR = 2.43, 95% CI = 1.73-3.46, p < .0001) and beyond 45 min (IRR = 3.75, 95% CI = 2.40-6.03, p < .0001) compared to patients with in-hospital seizure onset. Intermittent SE was a risk factor for more BZDs administered beyond 45 min compared to continuous SE (IRR = 1.44, 95% CI = 1.01-2.06, p = .04). Forty-seven percent of patients (n = 94) with out-of-hospital onset did not receive treatment before hospital arrival. Among patients with out-of-hospital onset who received at least two BZDs before hospital arrival (n = 54), 48.1% received additional BZDs at hospital arrival.

SIGNIFICANCE:

Failure to escalate from BZDs to non-BZD ASMs occurs mainly in out-of-hospital rSE onset. Delays in the implementation of medical guidelines may be reduced by initiating treatment before hospital arrival and facilitating a transition to non-BZD ASMs after two BZD doses during handoffs between prehospital and in-hospital settings.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estado Epiléptico / Epilepsia Resistente a Medicamentos Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Child / Child, preschool / Humans Idioma: En Revista: Epilepsia Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estado Epiléptico / Epilepsia Resistente a Medicamentos Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Child / Child, preschool / Humans Idioma: En Revista: Epilepsia Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos